RU2080322C1 - Производные полициклического гуанина - Google Patents

Производные полициклического гуанина Download PDF

Info

Publication number
RU2080322C1
RU2080322C1 RU9192016466A RU92016466A RU2080322C1 RU 2080322 C1 RU2080322 C1 RU 2080322C1 RU 9192016466 A RU9192016466 A RU 9192016466A RU 92016466 A RU92016466 A RU 92016466A RU 2080322 C1 RU2080322 C1 RU 2080322C1
Authority
RU
Russia
Prior art keywords
phenylmethyl
purin
methyl
imidazo
dimethyl
Prior art date
Application number
RU9192016466A
Other languages
English (en)
Russian (ru)
Other versions
RU92016466A (ru
Inventor
Нойштадт Бернард
Линдо Нил
Мэк Киттрик Брайн
Original Assignee
Шеринг Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Корпорейшн filed Critical Шеринг Корпорейшн
Publication of RU92016466A publication Critical patent/RU92016466A/ru
Application granted granted Critical
Publication of RU2080322C1 publication Critical patent/RU2080322C1/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Filtering Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
RU9192016466A 1990-06-21 1991-06-20 Производные полициклического гуанина RU2080322C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
US541568 1990-06-21
US541.568 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
RU92016466A RU92016466A (ru) 1995-05-20
RU2080322C1 true RU2080322C1 (ru) 1997-05-27

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9192016466A RU2080322C1 (ru) 1990-06-21 1991-06-20 Производные полициклического гуанина

Country Status (21)

Country Link
US (1) US5393755A (enExample)
EP (1) EP0538332B1 (enExample)
JP (1) JPH0747589B2 (enExample)
KR (1) KR960004532B1 (enExample)
AT (1) ATE155786T1 (enExample)
AU (1) AU651607B2 (enExample)
CA (1) CA2085733C (enExample)
CZ (1) CZ281920B6 (enExample)
DE (1) DE69126980T2 (enExample)
FI (1) FI925731A7 (enExample)
HU (1) HUT65623A (enExample)
IE (1) IE912126A1 (enExample)
IL (1) IL98559A0 (enExample)
NO (1) NO924940L (enExample)
NZ (1) NZ238609A (enExample)
OA (1) OA09723A (enExample)
PL (1) PL169481B1 (enExample)
RU (1) RU2080322C1 (enExample)
TW (1) TW197441B (enExample)
WO (1) WO1991019717A1 (enExample)
ZA (1) ZA914727B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2258705C2 (ru) * 1999-07-27 2005-08-20 Алмираль Продесфарма С.А. ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
RU2436777C2 (ru) * 2005-11-09 2011-12-20 Тосох корпорейшн Нуклеиновое основание, имеющее перфторалкильную группу и способ его получения

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939419A (en) * 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE395349T1 (de) * 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE60307628T2 (de) * 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
WO2005012293A1 (ja) * 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. フェニルアゾール化合物、製造法および抗酸化薬
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 v 억제제 제형
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
AU2006255028B2 (en) * 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
KR20100023040A (ko) * 2007-06-21 2010-03-03 쉐링 코포레이션 폴리사이클릭 구아닌 유도체 및 이의 용도
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
KR20110103949A (ko) * 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規調節タンパク質および阻害剤
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
CA2969594A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Pde2 inhibiting organic compounds
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
DE69033614T2 (de) * 1989-10-20 2001-04-19 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Kondensierte Purinderivate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Патент ЕПВ N 350742, кл. С 07 D 473/38, 1989. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2258705C2 (ru) * 1999-07-27 2005-08-20 Алмираль Продесфарма С.А. ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
RU2436777C2 (ru) * 2005-11-09 2011-12-20 Тосох корпорейшн Нуклеиновое основание, имеющее перфторалкильную группу и способ его получения

Also Published As

Publication number Publication date
US5393755A (en) 1995-02-28
HU9204032D0 (en) 1993-03-29
FI925731A0 (fi) 1992-12-17
ATE155786T1 (de) 1997-08-15
HUT65623A (en) 1994-07-28
FI925731A7 (fi) 1992-12-17
IE912126A1 (en) 1992-01-01
EP0538332B1 (en) 1997-07-23
CA2085733C (en) 1996-03-05
CA2085733A1 (en) 1991-12-22
AU651607B2 (en) 1994-07-28
TW197441B (enExample) 1993-01-01
NO924940D0 (no) 1992-12-18
WO1991019717A1 (en) 1991-12-26
CZ281920B6 (cs) 1997-04-16
NO924940L (no) 1992-12-18
EP0538332A1 (en) 1993-04-28
NZ238609A (en) 1993-12-23
JPH0747589B2 (ja) 1995-05-24
JPH05508647A (ja) 1993-12-02
PL169481B1 (pl) 1996-07-31
DE69126980D1 (de) 1997-09-04
DE69126980T2 (de) 1998-01-08
AU8199291A (en) 1992-01-07
IL98559A0 (en) 1992-07-15
ZA914727B (en) 1992-03-25
CZ374992A3 (en) 1993-10-13
OA09723A (en) 1993-08-30
PL297299A1 (enExample) 1992-07-13
KR960004532B1 (ko) 1996-04-06

Similar Documents

Publication Publication Date Title
RU2080322C1 (ru) Производные полициклического гуанина
US5641784A (en) 8-substituted 1,3-dialiphaticxanthine derivatives
EP2402334B1 (en) Inhibitors of E1 Activating Enzymes
JP5649614B2 (ja) 有機化合物
CA2687035C (en) Amino-heterocyclic compounds
HK1002935A1 (en) Pyrrolopyrimidine derivatives with antiproliferative action
DE69027562T2 (de) Xanthinverbindungen
HK1002935B (en) Pyrrolopyrimidine derivatives with antiproliferative action
JP3026020B2 (ja) 3環性プテリジノン類及びその製造方法
KR20200032146A (ko) Egfr 키나제 억제제로써의 아릴-인-산소 화합물
EP3719012A1 (en) Uracil compound as c-met/axl inhibitor
RU2737737C2 (ru) АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
JPH08507068A (ja) 2−ベンジル−多環式グアニン誘導体およびそれらの製造方法
JP2018513184A (ja) Pde1阻害剤としてのイミダゾトリアジノン
WO2008152387A1 (en) Quinazoline derivatives as pi3 kinase inhibitors
EP3315498A1 (en) Imidazo-pyrimidone compounds, and preparation method and application thereof
US5565463A (en) 9-subtituted-8-unsubstituted-9-deazaguanines
EP3738961B1 (en) Heterocyclic compound as csf-1r inhibitor and use thereof
MC1315A1 (fr) Derives de l'imidazole et leur synthese et preparation de medicaments contenant ces substances
CA2038747C (en) Selective adenosine receptor agents
US4943576A (en) Substituted quinoxalyl-imidazolidine-2,4-diones, processes for their preparation, their use as medicaments and pharmaceutical preparations
JPH0573754B2 (enExample)
AU2020101057A4 (en) Preparation method of adenosine receptor antagonist
CN116264834B (zh) 羟基嘌呤类化合物用于治疗皮肤疾病的用途
EP4617265A1 (en) Nitrogen-containing spirocyclic compound, pharmaceutical composition and use thereof